Hot Heal Care Stocks To Own Right Now

Intuit Inc (NASDAQ:INTU) files its latest 10-K with SEC for the fiscal year ended on July 31, 2017. Intuit Inc creates business and financial management solutions for small businesses, consumers, and accounting professionals. The company’s products and services include QuickBooks and TurboTax. Intuit Inc has a market cap of $36.36 billion; its shares were traded at around $141.90 with a P/E ratio of 38.14 and P/S ratio of 7.12. The dividend yield of Intuit Inc stocks is 0.97%. Intuit Inc had annual average EBITDA growth of 8.20% over the past ten years. GuruFocus rated Intuit Inc the business predictability rank of 3.5-star.

For the last quarter Intuit Inc reported a revenue of $842.0 million, compared with the revenue of $754.0 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $5.2 billion, an increase of 10.3% from last year. For the last five years Intuit Inc had an average revenue growth rate of 6% a year.

The reported diluted earnings per share was $3.72 for the year, an increase of 0.8% from previous year. Over the last five years Intuit Inc had an EPS growth rate of 5% a year. The Intuit Inc enjoyed an operating margin of 26.95%, compared with the operating margin of 26.46% a year before. The 10-year historical median operating margin of Intuit Inc is 26.71%. The profitability rank of the company is 9 (out of 10).

Hot Heal Care Stocks To Own Right Now: Pacific Biosciences of California Inc.(PACB)

Advisors’ Opinion:

  • [By Paul Ausick]

    Pacific Biosciences of California Inc. (NASDAQ: PACB) slipped about 5.6% to post a new 52-week low of $2.52 Tuesday after closing at $2.67 on Friday. Volume of about 910,000 was about 10% above the daily average. The company had no specific news.

Hot Heal Care Stocks To Own Right Now: Tel-Instrument Electronics Corp.(TIK)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of Tel-Instrument Electronics Corp. (NYSE: TIK) got a boost, shooting up 54 percent to $3.55 after the company reported $1 million of new orders.

  • [By Monica Gerson]

     

    General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion.
    Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million.
    Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million.
    Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion.
    Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million.
    Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million.
    UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million.
    Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million.
    OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million.
    8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million.
    Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million.
    Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million.
    Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million.
    Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter.
    Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share.
    Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea

Hot Heal Care Stocks To Own Right Now: KLX Inc.(KLXI)

Advisors’ Opinion:

  • [By Monica Gerson]

    KLX Inc (NASDAQ: KLXI) is projected to report its quarterly earnings at $0.30 per share on revenue of $383.62 million.

    Baozun Inc (ADR) (NASDAQ: BZUN) is expected to report its quarterly earnings at $0.19 per share on revenue of $610.98 million.

Hot Heal Care Stocks To Own Right Now: (MALRF)

Advisors’ Opinion:

  • [By SEEKINGALPHA.COM]

    The other producing lithium miners, and soon to be producers. I have discussed these previously in detail here, here and here. Needless to say, the top 3 producers are non-pure plays (SQM (NYSE:SQM), Albemarle (NYSE:ALB), and FMC Corp. (NYSE:FMC)). The top pure play currently producing miners are Orocobre (ASX:ORE) (OTCPK:OROCF), Tianqi Lithium (SHE:002466), Jiangxi Ganfeng Lithium, Galaxy Resources, Mineral Resources [ASX:MIN] (OTC:MALRF), and Neometals [ASX:NMT] (OTC:RRSSF). The near-term producers include Altura Mining [ASX:AJM] (OTCPK:ALTAF), Pilbara Minerals (ASX:PLS) (OTC:PILBF), Kidman Resources (ASX:KDR), Critical Elements, Nemaska Lithium (OTCQX:NMKEF) [TSX:NMX], Lithium Americas (OTCQX:LACDF) [TSX:LAC], Lithium X (OTCQX:LIXXF) (TSXV:LIX), Neo Lithium, and Bacanora Minerals (OTC:BCRMF) [TSXV:BCN], Advantage Lithium (OTCQB:AVLIF) [AAL], European Metals (OTCPK:MNTCF, ASX:EMH, AIM:EMH) and Pure Energy (OTCQB:PEMIF) [PE].

Hot Heal Care Stocks To Own Right Now: Orexigen Therapeutics, Inc.(OREX)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orexigen Therapeutics Inc. (NASDAQ: OREX) traded down about 78% Monday and posted a new 52-week low of $0.31 after closing Friday at $1.40. The stock’s 52-week high is $4.46. Volume was around 7.5million, about 15 times the daily average. The company has filed for Chapter 11 bankruptcy.

  • [By Cameron Saucier]

    Orexigen Therapeutics (Nasdaq: OREX) is a biopharmaceutical company that aims to treat obesity. The company’s flagship drug, Contrave, is approved by the Food and Drug Administration (FDA) in the United States. The drug regulates appetite, energy use, and the central nervous system. OREX rose 63% last month after it announced a new commercial and distribution agreement with Biologix FZCO. The agreement will cover 10 countries in the Middle East. OREX is currently trading at $3.30 per share and is down 79% as of Jan. 9 year over year (YOY).

  • [By Keith Speights]

    Arena is out of the obesity drug business, but what about Orexigen Therapeutics (NASDAQ:OREX) or VIVUS (NASDAQ:VVUS)? The problem is that they’re both too dependent on their respective obesity drugs, Contrave and Qsymia. Neither of the drugs have performed up to expectations.

  • [By Peter Graham]

    A long term chart shows Arena Pharmaceuticals along with its small capobesitytreatmentpeers EnteroMedics Inc (NASDAQ: ETRM), Orexigen Therapeutics, Inc (NASDAQ: OREX) and VIVUS, Inc (NASDAQ: VVUS) all causing severe weight loss for investor portfolios: